Login for faster access to the best deals. Click here if you don't have an account.

Senior Financial Analyst

2 years ago   Banking   Hyderabad   229 views Reference: 17705
Job Details

Job ID 342667BR

The role will help review and maintain the Financial Control & Compliance levels for the respective country

Position Purpose
• Understand business process, perform risk assessment, walkthroughs, conducting tests of design and operating effectiveness of controls
• Assess and analyze activities related to Segregation of duties
• Provide training and support to control owners to strengthen internal control compliance

Your responsibilities include, but are not limited to:
• Monitor and Report on Key Performance Indicators, analyze trends and provide insights on the overall controls and compliance to various local and global stakeholders
• Participate and perform high quality global Financial Controls and Compliance reviews for areas such as Account reconciliations and compliance with Novartis guidelines and SOX requirements
• Participate in projects such as controls harmonization across multiple business units and divisions, implementation of automated controls, controls data analytics

Minimum requirements

What you’ll bring to the role:
• CA/CPA/ACCA/ MBA Finance or Equivalent
• Excellent English (written and spoken)
• 3 to 5 year’s post qualification experience
• Prior working experience in a large Audit firm, preferably Big 4 Industry experience
• Internal/Statutory/ SOX 404 Audit
• Good Presentation and Communication Skills

Interested candidates Click on below link Apply Online and you will be redirected to Career Page of Company or Career url.

Company Description
Novartis was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its predecessor companies trace roots back more than 250 years, with a rich history of developing innovative products. From beginnings in the production of synthetic fabric dyes, the companies that eventually became Novartis branched out into producing chemicals and ultimately pharmaceuticals.